Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Neurochem Int ; 122: 38-46, 2019 01.
Article in English | MEDLINE | ID: mdl-30419255

ABSTRACT

Parkinson's disease (PD) is a frequent neurodegenerative disease causing bradykinesia, tremor, muscle rigidity and postural instability. Although its main pathology is progressive dopaminergic (DArgic) neuron loss in the substantia nigra, motor deficits are thought not to become apparent until most DArgic neurons are lost, probably due to compensatory mechanisms that overcome the decline of DA level in the striatum. Even in animal PD models, it is difficult to detect motor deficits when most DArgic neurons are functional. In this study, we performed various behavioral tests (apomorphine-induced rotation, cylinder, forepaw adjustment steps (FAS), beam walking, rota-rod, and open-field), using 6-hydroxydopamine (OHDA) and lipopolysaccharide (LPS)-induced hemi-PD model rats with various striatal DA levels, to find the best way to predict the DA level from earlier disease stages. Different from the 6-OHDA-induced model, reduction in the striatal DA levels in the LPS-model was less significant. Among the behavioral tests, data from cylinder and FAS tests, which evaluate forelimb movements, best correlated with decline of the DA level. They also correlated well with decreased body weight gain. The beam and apomorphine tests showed less significant correlation than the cylinder and FAS tests. Open-field and rota-rod tests were not useful. Expressional levels of mRNA encoding tyrosine hydroxylase (TH), a marker of DArgic neurons, correlated well with the DA level. Metabotropic glutamate receptor 4 mRNA expression correlated with the striatal DA level and may be related to compensatory mechanisms. These results suggest that motor impairments of PD should be evaluated by forelimb movements, or hands and forearms in clinical settings, rather than movement of the body or large joints. The combination of cylinder and FAS tests may be the best to evaluate the rat PD models, in which many DArgic neurons survive.


Subject(s)
Apomorphine/pharmacology , Behavior, Animal/drug effects , Dopamine Agonists/pharmacology , Parkinson Disease/drug therapy , Animals , Behavior Rating Scale , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Disease Models, Animal , Male , Motor Activity/drug effects , Nerve Degeneration/drug therapy , Nerve Degeneration/metabolism , Parkinson Disease/metabolism , Rats, Wistar , Substantia Nigra/drug effects , Substantia Nigra/metabolism
3.
Glia ; 66(10): 2158-2173, 2018 10.
Article in English | MEDLINE | ID: mdl-30194744

ABSTRACT

Microglia and blood-borne macrophages in injured or diseased brains are difficult to distinguish because they share many common characteristics. However, the identification of microglia-specific markers and the use of flow cytometry have recently made it easy to discriminate these types of cells. In this study, we analyzed the features of blood-borne macrophages, and activated and resting microglia in a rat traumatic brain injury (TBI) model. Oxidative injury was indicated in macrophages and neurons in TBI lesions by the presence of 8-hydroxy-2'-deoxyguanosine (8-OHdG). Generation of mitochondrial reactive oxygen species (ROS) was markedly observed in granulocytes and macrophages, but not in activated or resting microglia. Dihydroethidium staining supported microglia not being the major source of ROS in TBI lesions. Furthermore, macrophages expressed NADPH oxidase 2, interleukin-1ß (IL-1ß), and CD68 at higher levels than microglia. In contrast, microglia expressed transforming growth factor ß1 (TGFß1), interleukin-6 (IL-6), and tumor necrosis factor α at higher levels than macrophages. A hypnotic, bromovalerylurea (BU), which has anti-inflammatory effects, reduced both glycolysis and mitochondrial oxygen consumption. BU administration inhibited chemokine CCL2 expression, accumulation of monocytes/macrophages, 8-OHdG generation, mitochondrial ROS generation, and proinflammatory cytokine expression, and markedly ameliorated the outcome of the TBI model. Yet, BU did not inhibit microglial activation or expression of TGFß1 and insulin-like growth factor 1 (IGF-1). These results indicate that macrophages are the major aggravating cell type in TBI lesions, in particular during the acute phase. Activated microglia may even play favorable roles. Reduction of cellular energy metabolism in macrophages and suppression of CCL2 expression in injured tissue may lead to amelioration of TBI.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Brain Injuries, Traumatic/physiopathology , Bromisovalum/pharmacology , Hypnotics and Sedatives/pharmacology , Macrophages/physiology , Microglia/physiology , Animals , Brain Injuries, Traumatic/drug therapy , Brain Injuries, Traumatic/pathology , Cells, Cultured , Chemokine CCL2/metabolism , Disease Models, Animal , Macrophages/drug effects , Male , Microglia/drug effects , Oxidative Stress/drug effects , Oxidative Stress/physiology , Prosencephalon/drug effects , Prosencephalon/injuries , Prosencephalon/pathology , Prosencephalon/physiopathology , RNA, Messenger/metabolism , Rats, Wistar , Wounds, Stab/drug therapy , Wounds, Stab/pathology , Wounds, Stab/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...